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Differential inflammatory networks distinguish responses to bone
marrow-derived versus adipose-derived mesenchymal stem cell
therapies in vascularized composite allotransplantation
Ruben Zamora, PhD, Sudheer K. Ravuri, PhD, Jan A. Plock, MD,
Yoram Vodovotz, PhD, and Vijay S. Gorantla, MD, PhD, Pittsburgh, Pennsylvania
BACKGROUND: Vascularized composite allotransplantation (VCA) is aimed at enabling injured individuals to return to their previous lifestyles. Unfortu-
nately, VCA induces an immune/inflammatory response, which mandates lifelong, systemic immunosuppression, with attendant detrimen-
tal effects. Mesenchymal stem cells (MSC)—both adipose-derived (AD-MSC) and bone marrow–derived (BM-MSC)—can reprogram
inflammation and have been suggested as an alternative to immunosuppression, but their mechanism of action is as yet not fully elucidated.
We sought to gain insights into these mechanisms using a systems biology approach.
METHODS: PKH26 (red) dye-labeled AD-MSC or BM-MSC were administered intravenously to Lewis rat recipients of mismatched Brown-Norway
hindlimb transplants. Short course tacrolimus (FK-506) monotherapy was withdrawn at postoperative day 21. Sera were collected at
4 weeks, 6 weeks, and 18 weeks; assayed for 29 inflammatory/immune mediators; and the resultant data were analyzed using Dynamic
Network Analysis (DyNA), Dynamic Bayesian Network (DyBN) inference, and Principal Component Analysis.
RESULTS: DyNA network complexity decreased with time in AD-MSC rats, but increased in BM-MSC rats. DyBN and Principal Component Anal-
ysis suggested mostly different central nodes and principal characteristics, respectively, in AD-MSC versus BM-MSC rats.
CONCLUSION: AD-MSC andBM-MSC are associated with both overlapping and distinct dynamic networks and principal characteristics of inflammatory/
immunemediators in VCAgrafts with short-course tacrolimus induction therapy. The decreasing inflammatory complexity of dynamic net-
works in the presence of AD-MSC supports the previously suggested role for T regulatory cells induced by AD-MSC. The finding of some
overlapping and some distinct central nodes and principal characteristics suggests the role of key mediators in the response to VCA in general,
as well as potentially differential roles for other mediators ascribed to the actions of the different MSC populations. Thus, combined in vivo/in
silico strategies may yield novel means of optimizing MSC therapy for VCA. (J Trauma Acute Care Surg. 2017;83: S50–S58. Copyright ©
2017 Wolters Kluwer Health, Inc. All rights reserved.)
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V ascularized composite allotransplantation (VCA) is anemerging therapy for devastating trauma in both combat
and civilian settings, in selected subjects who have exhausted
conventional reconstructive or alternate treatment options. Over
200 VCAs, including 115 hand and 35 face transplants, have
been performed around the world in the past decade, with favor-
able immunologic, graft survival, and quality of life outcomes in
most patients.1 However, routine applicability and widespread
impact of VCA for catastrophic combat or civilian trauma will
only be realized if immunosuppressive risk is minimized and
functional outcomes are maximized.
Compelling experimental and clinical evidence in solid
organ transplant and VCA studies supports the role of bone
marrow–derived mesenchymal stem cells (BM-MSC) and
adipose-derived mesenchymal stem cells (AD-MSC) in promot-
ing modulation of the alloimmune response while augmenting
nerve regeneration and tissue repair.2–4 Such therapies have the
potential to refine current immunosuppressive approaches, to op-
timize functional outcomes and to increase clinical applicability
of VCA, thereby improving overall quality of life for injured ser-
vice members or civilians with devastating and disabling injuries
not amenable to conventional salvage/reconstructive strategies.
Inflammation is a key denominator in both trauma as well
as transplantation. Tissue damage and ischemia-reperfusion in-
jury that may occur in these two settings can induce a complex
host response driven by various cell types that produce endog-
enous danger signals, such as alarmins or damage-associated
molecular patterns, chemokines, and cytokines that disrupt
the immune homeostasis between inflammatory and anti-
inflammatory immune responses. Although, in transplantation,
this manifests as the host versus graft response (rejection) or
graft versus host response, in trauma such loss of immune ho-
meostasis is manifested by a continuum of phenomena that in-
volve overly exuberant systemic inflammation and attendant
immune anergy. This dysregulated response can cause loss of
immune competence in trauma patients, increasing the risk of
nosocomial infection and sepsis in much the same way that
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immunosuppression affects transplant recipients to increase the
risk of opportunistic infections.
The cellular and molecular mediators of the innate and
adaptive immune system do not function in isolation but rather
in complex and dynamic feedback interactions to either stimu-
late or suppress inflammation.5 Great progress has been made
in the understanding of how traumatic injury or transplantation
influences the immune system and how inflammation and im-
mune dysregulation affect in outcomes in either scenario, such
as sepsis or rejection. T regulatory (Treg) cells are versatile
and efficient regulators of the injury response and inflammation
in both transplant6 and trauma5 settings. In a similar vein, cell
therapies, such as AD-MSC or BM-MSC, are known to exert
their immunomodulatory or tolerogenic effects through Treg
cell–mediated mechanisms, especially of the adaptive immune
response.7,8
The skin of VCAs, such as hand or face transplants, is a
major locus for cellular inflammatory and immune reactivity
mediated and propagated by cytokines and chemokines. Inflam-
mation is thus a key driver of rejection post-VCA.9 Though
properly regulated inflammation allows for timely recognition
and repair of traumatic injury and subsequent VCA, insufficient10
or self-sustaining11 inflammation can lead to long-lasting immune
dysregulation.12 This prolonged immune dysregulation and ongo-
ing tissue damage, can, in turn, predispose to transplant rejection
in various contexts,13,14 including VCA.9,15
Taken together, insights into the intricate and complex dy-
namics underlying cellular, molecular, and genomic processes
underlying acute rejection (AR) are critical to the success of im-
munomodulatory or tolerance strategies in VCAs. In prior
studies, we demonstrated that dosing and timing of BM-MSC
and AD-MSC cell therapy are key variables in influencing im-
munomodulatory and graft survival outcomes after VCA.4 In
the current study, our goal was to investigate whether these im-
munomodulatory effects as manifested by suppression of AR
and prolongation of VCA survival are associated with specific
effects on dynamic inflammatory network patterns after VCA.
Using a systems biology approach, we examined dynamic net-
works and principal drivers of AR inVCA as a key to establishing
foundational understanding of downstream chronic pathological
processes including chronic rejection.
MATERIALS AND METHODS
Animals
All procedures involving animals complied with the regu-
lations regarding the care and use of experimental animals pub-
lished by the National Institutes of Health, and were approved by
the Institutional Animal Care and Use Committee of the Univer-
sity of Pittsburgh.
Orthotopic Limb Transplantation Surgical Technique
and Procedural Detail
Lewis rats received orthotopic hindlimb transplants from
full Major Histocompatibility Complex-mismatched Brown-
Norway (BN) donor rats. Isoflurane was used for inhalation
anesthesia. Bilateral shaved hind limbs of BN donors were
dissected through a circumferential skin incision, after ligation
of epigastric vessels, dissection of femoral vessels, and tran-
section at the level of the inguinal ligament. The two limbs
were amputated at midfemoral level and served as donor
limbs for two LEW recipients. Osteosynthesis was performed
using an intramedullary 18-gauge needle. Sciatic nerves were
coapted using 9-0 nylon sutures (Microsurgery Instruments,
Inc., Bellaire, TX), and the muscles sutured with interrupted 4-0
Vicryl stitches (Ethicon Inc., Somerville, NJ). Microsurgical
anastomosis of the femoral artery was performed with interrupted
11-0 nylon stitches, whereas a polyamide tube (RiverTech
Medical, Chattanooga, TN) was used as cuff for the femoral
vein, as reported earlier.
Isolation of BM-MSC and AD-MSC
The BM-MSCs were obtained from 6-week- to 8-week-
old BN rats by flushing long bones with Roswell Park Memorial
Institute 1640 medium (Lonza, Walkerville, MD). The cellular
pellet was erythrocyte-depleted, centrifuged, resuspended in
complete medium (Roswell Park Memorial Institute 1640 me-
dium, 10% fetal bovine serum, 2.5 μMHEPES [Sigma-Aldrich],
1% penicillin-streptomycin, 1.25 mg/L amphotericin B, 1%
l-glutamine, 1% sodium pyruvate, and 1% 2-mercaptoethanol
[all Gibco, Grand Island, NY]) and expanded in vitro until
passage 3. For injections, MSCs were lifted, counted, and re-
suspended (1  106 and 5  106 cells) in 1 mL of phosphate-
buffered saline for injection.
AD-MSC were isolated from inguinal adipose tissue ob-
tained from 6-week- to 8-week-old BN rats and digested enzy-
matically with collagenase type II (Worthington Biochemical
Corp, Lakewood, NJ) and bovine serum albumin (Millipore,
Billerica, MA) in Hanks balanced saline solution (Cellgro
Mediatech Inc. Manassas, VA) for 60 minutes at 37°C. After
centrifugation, the cellular pellet (stromal vascular fraction)
was erythrocyte-depleted by lysis buffer, filtered, and transferred
complete medium (Dulbecco's modified Eagle’s medium/F-12,
10% fetal bovine serum, 1% penicillin/streptomycin, 1.25 mg/L
amphotericin-B [all Gibco], 0.1 μM dexamethasone [Sigma-
Aldrich, St. Louis, MO]). The AD-MSCs were allowed to at-
tach for 6 hours, washed with phosphate-buffered saline, and
expanded until the third passage.
Characterization of BM-MSC and AD-MSC
Expanded cells were stained for CD29, CD73, CD90,
CD45, and RT1b (MHC I) and analyzed using a fluorescence-
activated cell sorter (Aria; Becton Dickinson, Franklin Lakes,
NJ). Data were analyzed using FlowJo software (TreeStar Inc.,
Ashland, OR).
MSC Treatment Protocol
Recipient animals were assigned to five groups: controls
(n = 5), 1  106 BM-MSCs (n = 6), 5  106 BM-MSCs (n = 7),
1  106 AD-MSCs (n = 8), and 5  106 AD-MSCs (n = 9).
All recipients were treated with rabbit anti-rat lymphocyte serum
(Cedarlane, Burlington, NC) 4 days before and 1 day after sur-
gery. Daily immunosuppression with tacrolimus (Astellas,
Chicago, IL) (FK-506; 0.5 mg/kg) was administered intraperi-
toneally from day 0 to postoperative day 21. The treatment
groups received a single MSC injection intravenously (i.v.)
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on postoperative day 1, injected slowly through the penile vein
using a 30-gauge needle. Animals were observed daily for
signs of rejection, assessed according to clinical VCA rejection
grading which is based on graft gross appearance.16 When re-
jection grade III was reached (experimental endpoint), animals
were killed for tissue sampling. In two nonrejecting animals,
BN donor skin grafts were transplanted to the neck to confirm
donor-specific tolerance after 120 days.
Analysis of Inflammatory Mediators
Rat inflammatory mediators were measured using a
Luminex 100 IS apparatus (Luminex, Austin, TX) and the rat
multiplex Luminex assay (Affymetricvs/Panomics, Santa Clara,
CA) as per manufacturer’s specifications. The antibody bead kit
included: β nerve growth factor (β NGF), Eotaxin (CCL11),
granulocyte colony-stimulating factor (G-CSF), granulocyte-
macrophage colony-stimulating factor (GM-CSF), keratinocyte-
derived cytokine (Gro-α/KC/CXCL1), intercellular adhesion
molecule-1 (ICAM-1), interferon-γ (IFN-γ), interleukin (IL)-
1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p40, IL-12p70,
IL-13, IL-17A, IFN-γ–inducible protein 10 (IP-10/CXCL10),
leptin, monocyte chemoattractant protein (MCP) (MCP-1/
CCL2, and MCP-3/CCL7), macrophage inflammatory protein-1α
(MIP-1α/CCL3), MIP-2/Gro-β, tumor necrosis factor-α (TNF-α),
regulated on activation, normal T cell expressed and secreted
(RANTES/CCL5), receptor activator of nuclear factor κ-B
Ligand (RANKL), vascular cell adhesion molecule 1 (VCAM-1)
and vascular endothelial growth factor-A (VEGF-A). The final
mediator concentrations are expressed in pg/mL. Experimental
data are presented as mean ± SEM.
Statistical and Computational Analyses
(1) Two-way analysis of variance (ANOVA) was carried
out to analyze the changes in inflammatory mediators using
SigmaPlot (Systat Software, San Jose, CA) as indicated.
(2) Principal component analysis (PCA) and time-interval
PCA (TI-PCA) were carried out to identify the inflammatory
mediators that contributed the most to the overall variance of
the response in serum of rats that underwent hind-limb VCA
along with i.v. injection of AD-MSCs or BM-MSCs (4, 6 and
18 weeks) using normalized data, as described.17 Data were
not binned. PCA and TI-PCA were performed using Matlab
software (The MathWorks, Inc., Natick, MA).17
(3) Dynamic Network Analysis (DyNA) was carried out
to define the central inflammatory network nodes as a function
of both time and treatment. Rats underwent hind-limb VCA
along with i.v. injection of AD-MSCs or BM-MSCs as de-
scribed and serum samples were obtained at 4, 6, 18 weeks.
Using inflammatory mediator measurements of three time-
points for each experimental group, networks were created over
two consecutive periods (4–6 weeks and 6–18 weeks) using
Matlab software;17,18 data were not binned. Connections (or
number of trajectories of serum inflammatory mediators that
move in parallel) were created if the Pearson correlation coef-
ficient between any two nodes (inflammatory mediators) at
the same time interval was greater or equal to a threshold of
0.7 or 0.95, as indicated. The network complexity for each
time interval was calculated using the following formula:
Sum (N1 + N2 +…+ Nn)/n−1, where N represents the number
of connections for each mediator, and n is the total number of
mediators analyzed.
(4) Dynamic Bayesian Network (DyBN) inference was
carried out to define the most likely single network structure that
best characterizes the dynamic interactions among systemic in-
flammatory mediators across all timepoints, in the process sug-
gesting likely feedback structures that define central nodes.
The networks may also suggest possible mechanisms by which
the progression of the inflammatory response differs within
a given experimental subgroup. In this analysis, time courses
of unprocessed inflammatory mediator measurements were used
as input for a DyBN inference algorithm, implemented in
Matlab essentially as described previously for gene array data19
and modified by our group for the study of systemic acute
inflammation.20–22
RESULTS
We have described the differential impact of AD-MSC
and BM-MSC on VCA.3,4 Herein, we sought to define the im-
pact of these MSC populations on dynamic networks of sys-
temic inflammation and immunity.
Characterization of AD-MSC and BM-MSC
The MSCs from BM and adipose tissue were character-
ized using flow cytometry. Both cell lines were negative for
the hematopoietic marker CD45 (0.46% for BM-MSCs and
0.48% for AD-MSCs. Both cell types expressed high levels of
CD29 (99.7% vs. 97.1%), CD90 (98.0% vs. 94.3%), and CD73
(93.6% vs. 90.5%).
Effects of AD-MSCs Versus BM-MSCs on Circulating
Levels of Inflammatory Mediators After VCA
We hypothesized that the effects of MSCs on suppressor
function, Treg cell induction, and chimerism we observed were
associated with an altered balance of systemic inflammatory
mediators after VCA. Accordingly, we initially analyzed the
dynamics of circulating cytokines/chemokines by two-way
ANOVA. The time-courses of inflammatory mediators are shown
in Suppl. Fig. 1 (see Figure., Supplemental Digital Content 1,
http://links.lww.com/TA/A939). This analysis suggested dif-
ferent dynamics of multiple mediators, but did not reveal statis-
tically significant differences between the two experimental
groups (all P values > 0.05).
DyNA of Inflammatory Mediators Suggests a
Differential Network Complexity in AD-MSCs Versus
BM-MSCs After VCA
Since standard statistical analysis of the inflammatory me-
diator data did not serve to differentiate between AD-MSCs and
BM-MSCs after VCA, and given that the data are diverse, com-
plex, and, for many mediators, nonlinear, we applied more
advanced computational tools aimed at discerning principal
characteristics and dynamic networks.17,18,20
DyNA was used to discern novel and potentially non-
intuitive central inflammatorymediators involved in, or biomarkers
of, the response to VCA across the three time points after treatment
Zamora et al.
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with either AD-MSCs or BM-MSCs. As shown in Figure 1, dy-
namic network complexity decreased with time in rats treated
with AD-MSCs. These networks involved a large number of
mediators (in decreasing order of connectivity) as depicted in
Table 1. In contrast, DyNA network complexity increased as a
function of time in rats treated with BM-MSCs (Fig. 2), and in-
volved a large number of mediators (in decreasing order of con-
nectivity) as depicted in Table 2.
DyBN Inference Suggests Different Motifs in
AD-MSCs Versus BM-MSCs After VCA
We next used DyBN inference18,20,22,23 to describe the
overall feedback structure of the systemic inflammatory networks
associated with AD-MSC versus BM-MSC and to discern poten-
tial central inflammatory nodes in response to AD-MSCs versus
BM-MSCs. In rats subjected to VCA + AD-MSCs, central
nodes (those network mediators exhibiting self-feedback as well
as multiple effects on downstream nodes) were inferred to be
ICAM-1, Leptin, and MIP-2 (Fig. 3A). In contrast, in rats
subjected to VCA and BM-MSCs, central nodes were inferred
to be VCAM-1, Leptin, MIP-2, and RANKL (Fig. 3B). These
findings partially confirmed the findings obtained by DyNA
(Tables 1 and 2).
Differential Principal Characteristics of Inflammation
in AD-MSCs Versus BM-MSCs After VCA Based on
PCA and Time Interval PCA
Finally, we used PCA to define the primary dynamic char-
acteristics of systemic inflammation in response to AD-MSCs
versus BM-MSCs across these same time points (Fig. 4). This
analysis suggested that the primary inflammatory characteristics
or mechanisms of VCA + AD-MSCs involved IL-1β, RANTES,
IL-2, IL-6, and eotaxin (Fig. 4A). In contrast, the primary
Figure 1. DyNA network complexity in rats undergoing VCA
along with AD-MSCs. Rats underwent hindlimb VCA along with
i.v. injection of 5 106 PKH26 (red) dye-labeled BN rat AD-MSCs
as described in Materials and Methods. Serum samples were
collected at 4, 6, 18 weeks and assayed for 29
inflammatory/immune mediators using the rat multiplex
Luminex assay. DyNA was performed during the following two
timeframes: 4 weeks to 6 weeks and 6 weeks to 18 weeks as
indicated. (A) An overview of the networks and mediator
connections (stringency level = 0.95). (B) The network
complexity calculated as described in Materials and Methods.
TABLE 1. Rats Underwent Hindlimb VCA Along With i.v.
Injection of 5 106 PKH26 (red) Dye-Labeled BNRat AD-MSCs as
Described in Materials and Methods
Mediators 4–6 weeks 6–18 weeks Total
IL-2 5 4 9
MCP-1 6 3 9
MCP-3 5 3 8
IP-10 5 2 7
Leptin 5 2 7
MIP-2/GROβ 5 2 7
RANKL 5 2 7
Eotaxin/CCL11 6 0 6
IL-12/IL-23p40 5 1 6
IL-13 5 1 6
RANTES 6 0 6
GM-CSF 2 3 5
IL-1β 4 1 5
VEGF-A 5 0 5
IL-10 3 0 3
IL-6 0 3 3
β NGF 2 0 2
G-CSF 2 0 2
IL-12p70 2 0 2
ICAM-1 1 1 2
IL-1α 0 2 2
IL-4 2 0 2
GROα/KC 0 1 1
IL-17A 1 0 1
IL-5 0 1 1
MIP-1a 0 1 1
VCAM-1 0 1 1
IFN-γ 0 0 0
TNF-α 0 0 0
Serum samples were collected at 4 weeks, 6 weeks, 18 weeks, and assayed for 29
inflammatory/immune mediators using the rat multiplex Luminex assay. DyNA was per-
formed during the following two timeframes: 4 weeks to 6 weeks and 6 weeks to
18weeks as indicated. Table shows the numbermediator connections (stringency level = 0.95)
as determined by DyNA.
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inflammatory characteristics or mechanisms of VCA/BM-MSCs
were inferred to involve IL-13, RANKL, MIP-2, RANTES, and
IL-2 (Fig. 4B). Furthermore, we developed a method (time inter-
val PCA; TI-PCA) to identify those inflammatory mediators that
contributed the most to the overall variance of the inflammatory
response in both experimental groups over two consecutive pe-
riods (4–6 weeks and 6–18 weeks). The results of this analysis
and the top five inflammatory mediators for each time interval
are shown in Figure 4C (AD-MSCs) and Figure 4D (BM-MSCs).
DISCUSSION
The present study was aimed at defining, at least in part,
some of the modulatory effects of AD-MSC and BM-MSC on
VCA-induced systemic inflammation. Our results suggest that,
in concert with prolonging survival of immunogenic skin-
bearing VCA grafts,4 these different MSC types exert variable
immunosuppressive effects along with distinct impacts on dy-
namic inflammatory network complexity.
In vivo, all animals revealed peripheral multilineage chi-
merism at 4 weeks (p < 0.01) independent of cell type and dos-
age.4 These initial studies also showed that both AD-MSC and
BM-MSC could drive a strong, dose-dependent suppressor
function in vitro, though this effect was significantly more pro-
nounced for AD-MSC.4 This, in concert with more pronounced
Treg cell levels and better survival in AD-MSC as compared to
BM-MSC, led us to hypothesize that AD-MSC somehow im-
pacted VCA-induced systemic inflammation differentially.
Our findings based on DyNA suggest increasing dynamic
evolution of networks of systemic inflammation in rats under-
going VCA. We found that dynamic network complexity de-
creased with time in rats treated with AD-MSC, whereas the
opposite was true in rats treated with BM-MSC. The signifi-
cance of this finding is currently under investigation. However,
we have suggested previously that trends toward increasing in-
flammatory network complexity as assessed by DyNA is often
associated with adverse outcomes such as mortality after
Figure 2. DyNA network complexity in rats undergoing VCA
along with BM-MSCs. Rats underwent hind-limb VCA along with
i.v. injection of 5 106 PKH26 (red) dye-labeled BN rat BM-MSCs
as described in Materials and Methods. Serum samples were
collected at 4 weeks, 6 weeks, 18 weeks, and assayed for 29
inflammatory/immune mediators using the rat multiplex
Luminex assay. DyNA was performed during the following two
timeframes: 4 weeks to 6 weeks and 6 weeks to 18 weeks as
indicated. (A) An overview of the networks and mediator
connections (stringency level = 0.95). (B) The network
complexity calculated as described in Materials and Methods.
TABLE 2. Rats Underwent Hindlimb VCA Along With i.v.
Injection of 5  106 PKH26 (red) Dye-Labeled BN Rat BM-MSCs
as Described inMaterials and Methods
Mediators 4–6 weeks 6–18 weeks Total
RANKL 3 8 11
IL-13 3 7 10
β NGF 2 7 9
GM-CSF 4 5 9
ICAM-1 3 6 9
IL-2 3 6 9
MCP-3 3 5 8
Eotaxin/CCL11 3 4 7
MCP-1 0 7 7
MIP-2/GROβ 3 4 7
IL-12/IL-23p40 0 6 6
VCAM-1 4 2 6
IL-12p70 5 0 5
IL-1β 3 2 5
IP-10 0 5 5
RANTES 0 5 5
GROα/KC 4 0 4
Leptin 0 4 4
MIP-1a 4 0 4
IL-1α 0 3 3
IL-5 3 0 3
IFN-γ 2 0 2
IL-4 2 0 2
IL-6 0 1 1
TNF-α 0 1 1
G-CSF 0 0 0
IL-10 0 0 0
IL-17A 0 0 0
VEGF-A 0 0 0
Serum samples were collected at 4 weeks, 6 weeks, 18 weeks, and assayed for 29
inflammatory/immune mediators using the rat multiplex Luminex assay. DyNA was per-
formed during the following two time frames: 4 weeks to 6 weeks and 6 weeks to
18weeks as indicated. Table shows the numbermediator connections (stringency level = 0.95)
as determined by DyNA.
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trauma24 or in the setting of pediatric acute liver failure.25 In the
trauma setting, increasing inflammatory network complexity
was paralleled by increasing multiple organ dysfunction.24 We
thus hypothesize a potentially greater benefit of AD-MSC vs.
BM-MSC. In support of this hypothesis, AD-MSC treatment re-
sulted in long-term (>120 day) allograft survival in 47% of the
animals, which correlated with durable microchimerism in bone
marrow and spleen.4 Although both AD-MSC and BM-MSC
exhibited strong, dose-dependent suppressor function in vitro,
this was significantly more pronounced for AD-MSC.4 Finally,
Treg cell levels were increased with both cell types, but to a
higher degree in AD-MSC rats,4 again suggesting a potentially
greater benefit for AD-MSC in VCA (summarized in Fig. 5;
see further discussion below). However, long-term immuno-
modulatory effects remain uncertain and require further study.
In parallel, we have found that dynamic inflammatory net-
works start out at higher complexity and then decrease in trauma
patients who resist nosocomial infections.26 This and other prior
studies have raised the possibility of positive feedback in the sys-
temic inflammatory response that is sustained or promoted by
multiple pathways, including innate immune and Th17-related
mechanisms, and kept in check via Treg cells.24 These hypothe-
ses are supported by our current data in VCA: rats treated with
AD-MSC exhibit decreasing complexity of systemic inflamma-
tory networks in concert with elevated Treg cells, whereas ani-
mals treated with BM-MSC display the opposite phenotype.
Further studies are needed, however, to help prove or disprove
this hypothesis.
Our analyses as a whole suggested that multiple cytokines
and chemokines were differentially interconnected in rats
treated with AD-MSC versus BM-MSC. Based on DyNA,
the top 10 most connected mediators in rats treated with
AD-MSC included IL-2, MCP-1, MCP-3, IP-10, leptin, MIP-2,
eotaxin, IL-12, IL-13, and RANTES. In rats treated with
BM-MSC, the top 10 most connected mediators were RANKL,
IL-13, β-NGF, GM-CSF, ICAM-1, IL-2, MCP-3, eotaxin,
MCP-1, and MIP-2. These differential connectivity patterns
suggest a conserved signature of response to VCA with or
without treatment with MSCs, consisting of pathways driven
by IL-2, IL-13, MCP-1, MCP-3, MIP-2, and eotaxin. AD-MSC–
specific systemic inflammation appears to include pathways
driven by IP-10, leptin, IL-12, and RANTES, whereas BM-MSC
appear to stimulate pathways driven by RANKL, β-NGF,
GM-CSF, and ICAM-1.
Our data show that IL-2 is an important driver of networks
after AD-MSC treatment. Activated T cells produce IL-2. Treg
cells abundantly express the IL-2 receptor, and IL-2 is a driver
of Treg cell suppressor activity. This suggests that perhaps this
mediator is a hallmark of Treg cell induction by MSCs. Our
prior findings in VCA confirmed that both AD-MSC and
BM-MSC exhibited strong, dose-dependent suppressor function
in vitro, which was significantly more pronounced for AD-MSC.
In vivo, all animals revealed peripheral multilineage chimerism at
4 weeks, independent of cell type and dosage. Treg cell levels
were increased with both cell types, but more in the AD-MSC
treatment groups.4 Furthermore, AD-MSC treatment resulted in
Figure 3. Differential DyBN network patterns in rats undergoing VCA along with AD-MSCs vs. BM-MSCs. Rats underwent hind-limb
VCA along with i.v. injection of 5  106 PKH26 (red) dye-labeled BN rat AD-MSCs or BM-MSCs as described in Materials and
Methods. Serum samples were obtained at 4 weeks, 6 weeks, 18 weeks, and assayed for 29 inflammatory/immune mediators using
the ratmultiplex Luminex assay followed byDyBN analysis as described inMaterials andMethods. (A and B) The inflammatory networks
for AD-MSCs and BM-MSCs, respectively.
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long-term (>120 day) allograft survival in 47% of the animals,
which correlated with durable microchimerism in bone marrow
and spleen.4
Both AD-MSC and BM-MSC are known to induce Treg
cells from effector T cells as well as expanded natural Treg
(nTreg) cell. nTreg and induced Treg (iTreg) cells can be distin-
guished by not only their origin but also by differences in the ex-
pression of the transcription factor, FOXP3 and methylation
pattern of the Treg cell–specific demethylated region in the
FOXP3 gene.27 Both Treg cell types have similar immunoregu-
latory effects, but a longer lifespan, when compared to MSC,
which is only approximately 24 hours after infusion.28 The supe-
rior efficacy of AD-MSC versus BM-MSC in prolonging graft
survival in our study possibly relates to their differential ability
to sustain the persistence of Treg cells in the recipients long after
administration, as well as the dynamic inflammation networks
that emerge thereafter in the presence of increased numbers of
Treg cells. Although we did not study the expression or methyl-
ation patterns of FOXP3 in Treg cell subsets in our study, we
postulate that AD-MSC-stimulated iTreg cells might help drive
an anti-inflammatory program that is in part driven by IP-10
(as we have suggested previously, based on analysis of dynamic
networks, in the response to traumatic injury). In contrast, we
hypothesize that nTreg cells are predominantly induced by
BM-MSC and are consequently less effective at reducing rejec-
tion (Fig. 5). This hypothesis will be a focus of future studies in
our lab.
It is also tempting to speculate that BM-MSC may help
drive nerve regeneration based on the triggering of β-NGF.
RANTES is a chemokine that is involved in multifaceted
chemoattraction of lymphocytes, and has been associated with
chronic rejection in the context of transplantation.29 Interest-
ingly, this chemokine has also been reported to be elevated after
treatment with a human BM-MSC line in a spinal cord injury
paradigm,30 supporting the emerging concept that the immuno-
modulatory properties of MSCs may be context-specific.31
It is important to note that the foregoing hypotheses, and
potentially numerous others, could not have been derived with-
out the use of advanced computational modeling techniques as
used in the current study. Static cytokine measurements of in-
flammation or rejection remain the conventional accepted stan-
dard in research. However, such methods failed to show
statistically significant differences in the current study because
they are not capable of discerning the complex dynamic inter-
connectivity among the myriad mediators as analyzed. Further
studies with a larger panel of mediators are needed to test these
hypotheses and better define the potential mechanisms that un-
derlie the in vivo efficacy of AD-MSC versus BM-MSC thera-
pies in the setting of VCA. However, our results demonstrate
the utility of our computational methods for suggesting novel
hypotheses that can be tested in future studies.
Strategies aiming at minimization or elimination of sys-
temic immunosuppression are key immediate goals for clinical
expansion of VCA. The importance and relevance of dynamic
network complexity during inflammation, and their relation to
outcomes in related fields, such as traumatic injury,22,24,26,32–34
reinforces the rationale for similar studies in VCA. Our in silico
results offer key primary insights into similar mechanisms in
VCA. Further exploration of key drivers as well as complexity
Figure 4. Differential primary inflammatory characteristics in
rats undergoing VCA along with AD-MSCs versus BM-MSCs as
discerned by PCA and TI-PCA. Rats underwent hindlimb VCA
along with i.v. injection of 5  106 PKH26 (red) dye-labeled BN
rat AD-MSCs or BM-MSCs as described in Materials and
Methods. Serum samples were obtained at 4 weeks, 6 weeks,
18 weeks, and assayed for 29 inflammatory/immune mediators
using the rat multiplex Luminex assay followed by PCA and
TI-PCA as described in Materials and Methods. (A and B) The
inflammatory characteristics of AD-MSCs and BM-MSCs,
respectively. The top five inflammatorymediators are highlighted
for both groups. (C and D) The inflammatory characteristics and
top five inflammatory mediators for each time interval of
AD-MSCs and BM-MSCs, respectively.
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of cytokine networks during early inflammatory or immune
events after VCA (such as ischemia reperfusion injury and sur-
gical inflammation) may help identify promising cellular or mo-
lecular targets for rational treatment interventions in VCA.
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